PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies

July 10, 2025

In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX’s lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into the company’s strategic pathway, including FDA fast track designation and potential market opportunities exceeding $1.8 billion. Learn how PTX’s targeted Ras pathway disruption could unlock new treatments for multiple cancers like lung, pancreatic, and biliary tumours. The conversation also covers funding strategies, the impact of government R&D incentives, and upcoming milestones that could accelerate PTX’s journey to market. Whether you’re an early stage biotech investor or interested in innovative cancer therapies, this interview provides valuable insights into PTX’s potential to revolutionise oncology care.

Watch the full interview below.

Related Post

This investor centre was built by Reach Markets

©2026 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.